Skip to content
Open access

Outcomes of As-Needed Aflibercept Treatment After Complete Regression in Polypoidal Choroidal Vasculopathy.

Sep 2026 · JAMA ophthalmology · 0 citations · 14 references
Medicine

TL;DR

Half of the eyes with PCV achieved complete polypoidal regression remained quiescent after treatment deferral, whereas the remainder recurred, and posttreatment OCT biomarkers may help identify eyes that could benefit from continued treatment instead of PRN management.

Abstract

Importance Complete polypoidal regression (termed regression) is a treatment goal in polypoidal choroidal vasculopathy (PCV), a common cause of vision loss globally. However, outcomes are controversial when treatments continue as fixed-dosing, treat-and-extend, or as-needed (PRN) regimens once regression is achieved. Objective To determine outcomes using PRN regimens after achieving complete polypoidal regression following an initial treatment of 3 or 6 monthly intravitreal anti-vascular endothelial growth factor injections in eyes with PCV. Design, Setting, and Participants This prospective cohort study took place at 4 university hospitals in Thailand. Eighty-one treatment-naive participants with PCV received 3 monthly aflibercept 2.0-mg injections. At week 12, eyes with regression underwent PRN treatment and follow-up monthly during year 1 and bimonthly during year 2. Eyes without regression at week 12 received 3 additional monthly injections and if regressed at week 24, also underwent PRN treatment and follow-up monthly through year 1 and bimonthly follow-up through year 2. Eyes without regression through week 24 received treat-and-extend regimens. These data were analyzed from August 2020 to September 2025. Main Outcomes and Measures Fluid-free interval between first visit with regression and first exudative recurrence on optical coherence tomography (OCT) by life-table analyses. Results Of 81 study eyes, mean [SD] age was 64 [8] years; 54% were female and 46% were male; 32 (40%) achieved regression at week 12 or 24. Of 26 eyes with regression, 13 (50%; 95% CI, 30%-70%) recurred within 2 years. Fluid-free probability after regression was 57% (95% CI, 37%-77%) at week 24 and 53% (95% CI, 33%-73%) at week 84. Among 14 eyes with recurrence, median best-corrected visual acuity change from the prior visit was -3.5 letters (IQR, -5.0 to -0.25); 3 (21%; 95% CI, 5%-51%) lost 10 or more letters, and 5 (36%; 95% CI, 13%-65%) had new hemorrhage. Post hoc exploratory analyses of eyes with complete polypoidal regression showed baseline massive subretinal hemorrhage had lower recurrence (hazard ratio [HR], 0.18; 95% CI, 0.04-0.80; P = .01). In contrast, leakage without subretinal hemorrhage may have had a higher hazard of recurrence (HR, 2.65; 95% CI, 0.89-7.94; P = .07). Conclusions and Relevance In this study, half of the eyes with PCV achieved complete polypoidal regression remained quiescent after treatment deferral, whereas the remainder recurred. Posttreatment OCT biomarkers may help identify eyes that could benefit from continued treatment instead of PRN management.

Read PDF

Similar papers

Review Oct 2026

The Clinical Significance of Polypoidal Lesion Regression in Polypoidal Choroidal Vasculopathy - A Review.

Achieving complete polypoidal lesion regression is a critical clinical endpoint for ensuring long-term disease stability and reducing the risk of catastrophic recurrence and should nonetheless be regarded as one of several important endpoints - alongside visual acuity, exudative control, safety, and treatment accessibi...

Jun-Wei Chen, De-Kuang Hwang, Yi-Ting Hsieh et al. · 0 citations
Open access Nov 2026

Real-World Twelve-Month Outcomes of Switching from Aflibercept to Faricimab in Chinese Neovascular Age-Related Macular Degeneration with Inadequate Aflibercept Response

Purpose To evaluate 12-month outcomes of switching to faricimab in eyes with neovascular age-related macular degeneration (nAMD) in Chinese patients showing inadequate response to aflibercept, and explore correlations between dynamic changes in subretinal hyperreflective material (SHRM) height, treatment interval and v...

Jing Wang, Feng-Jiao Li, Ya-Lin Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.